Scotland as a test bed for outcomes-based reimbursement
Most cancer drugs granted accelerated approval by the US Food and Drug Administration between 2013 and 2017 still had no demonstrated survival or quality-of-life benefit by mid-2023 (Liu et al., JAMA, 2024). Through Project Orbis the MHRA now reviews many of the same applications concurrently with the FDA, so drugs arrive in England and Scotland […]